{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T22:02:40Z","timestamp":1757455360716},"reference-count":0,"publisher":"American Association for Cancer Research (AACR)","issue":"4_Supplement","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Introduction: Multidisciplinary tumor boards (MTB) offer patients (pts) access to multidisciplinary care and may lead to more efficient, cost-effective and evidence-based treatments and better outcomes. Data regarding the implementation and functioning of breast cancer (BC) MTB worldwide and according to countries\u2019 income are lacking. Methods: We developed a survey, which was disseminated to healthcare professionals working in BC through the use of social networks and emails (accessible from 15 May to 3 July 2020). Countries\u2019 income classification was defined according to the World Bank Atlas method. Results: We obtained 675 responses from 71 countries (40% Western Europe, 14% Eastern Europe, 13% Latin America, 13% Asia, 11% Oceania, 5% North America, 3% Africa; 71% high income, 28% middle income, 1% low income countries). More than half of the respondents were medical oncologists (55%), followed by surgical oncologists (12%), clinical oncologists (11%) and radiation oncologists (7%). Over 60% were between 30-49 years of age and 55% had &amp;gt;10 years of medical practice. MTBs from academic institutions (43%), dedicated cancer centers (30%), public (19%) and private (18%) institutions were reported. Overall, 11% of respondents do not have regular MTBs in their institution, with discrepancies among regions: 34% of respondents from Asia, 18% from Africa, 17% from Eastern Europe, 14% from Latin America, 3% from Western Europe, 2.6% from Oceania and none from North America. This corresponds to 43% of respondents from low income, 22% from middle income and 5.6% from high income countries. Among these, 42% have their patients informally discussed between departments, 23% within a single department and the decision is taken only by the attending physician in 31% of the cases. Eighty-nine percent of respondents (N=602) have regular MTBs, of which 69% are dedicated to BC; 71% discuss all stage I-IV BC cases before any treatment decision, whereas 18% only present new BC cases, before starting any form of treatment and 11% discuss only early BC cases. Above 80% have &amp;gt;4 disciplines represented (18% have 1-3, 44% 4-6, 37% 7-9 and 13% &amp;gt;10). The most represented discipline is medical oncology (98%), followed by surgical oncology (94%), radiation oncology (90%), pathology (87%) and radiology (80%), among others. A nurse is present in 49% of MTB, a psychologist\/psychiatrist in 19%, a social worker in 11% and the doctor in charge of the patient in 25%. Pts are not present in 80% of MTB in high income countries, in 44% in middle income and in 29% in low income. Half of respondents reported that it is not mandatory for the treating doctor to implement the decision of the MTB. For 72%, the decision of the MTB is implemented in &amp;gt;75% of the cases, but only 24% have a quality control to check this. When asked about the results of an effective BC MTB, respondents agreed that it resulted in improved clinical decision making (95%), more coordinated patient care (86%), evidence-based treatment decisions (89%), shorter time to tests\/treatments (60%) and improved survival (50%). During the COVID19 pandemic, 5% of all MTB were cancelled, 50% switched to virtual meetings, 16% maintained physical MTB with adjustments (social distance\/personal protective equipment). Only 7% believe that all MTB will remain virtual, 40% think that MTB will return to their original physical version and 53% that there will be an alternating scheme. Conclusions: The vast majority of participants reported having regular MTBs in their institution, with a high rate of uptake of MTB recommendations. Differences in the implementation of MTB according to the countries\u2019 level of income can be observed and highlights the need to scale-up MTB coverage around the world, especially in low\/middle income countries. The COVID19 pandemic led to a high adoption of virtual MTB, which may have long-term effects.<\/jats:p>\n               <jats:p>Citation Format: Rita Sa\u00fade-Conde, Sofia Ferreira, Mariana Brand\u00e3o, Gil Morgan, Evandro de Azambuja. Multidisciplinary Tumor Board in Breast Cancer: Results from a large international survey involving 71 countries [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS7-22.<\/jats:p>","DOI":"10.1158\/1538-7445.sabcs20-ps7-22","type":"journal-article","created":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T11:15:26Z","timestamp":1613387726000},"page":"PS7-22-PS7-22","update-policy":"http:\/\/dx.doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Abstract PS7-22: Multidisciplinary Tumor Board in Breast Cancer: Results from a large international survey involving 71 countries"],"prefix":"10.1158","volume":"81","author":[{"given":"Rita","family":"Sa\u00fade-Conde","sequence":"first","affiliation":[{"name":"1Department of Medical Oncology, Instituto Portugu\u00eas de Oncologia de Lisboa, Lisboa, Portugal"}]},{"given":"Sofia","family":"Ferreira","sequence":"additional","affiliation":[{"name":"1Department of Medical Oncology, Instituto Portugu\u00eas de Oncologia de Lisboa, Lisboa, Portugal"}]},{"given":"Mariana","family":"Brand\u00e3o","sequence":"additional","affiliation":[{"name":"2Academic Trials Promoting Team, Institut Jules Bordet et L\u2019Universit\u00e9 Libre de Bruxelles (U.L.B.), Brussels, Belgium"}]},{"given":"Gil","family":"Morgan","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Sk\u00e5ne University Hospital, Lund, Sweden"}]},{"given":"Evandro","family":"de Azambuja","sequence":"additional","affiliation":[{"name":"2Academic Trials Promoting Team, Institut Jules Bordet et L\u2019Universit\u00e9 Libre de Bruxelles (U.L.B.), Brussels, Belgium"}]}],"member":"1086","container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/81\/4_Supplement\/PS7-22\/648780\/Abstract-PS7-22-Multidisciplinary-Tumor-Board-in","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/81\/4_Supplement\/PS7-22\/648780\/Abstract-PS7-22-Multidisciplinary-Tumor-Board-in","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,22]],"date-time":"2022-06-22T09:38:26Z","timestamp":1655890706000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/81\/4_Supplement\/PS7-22\/648780\/Abstract-PS7-22-Multidisciplinary-Tumor-Board-in"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":0,"journal-issue":{"issue":"4_Supplement","published-print":{"date-parts":[[2021,2,15]]}},"URL":"https:\/\/doi.org\/10.1158\/1538-7445.sabcs20-ps7-22","relation":{},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]}}}